IL2 and COVID-19: In addition to increased IL-6 levels, an increase in levels of C-Reactive Protein (CRP), IL-1β, IL-2 and Tumour Necrosis Factor (TNF) has been observed in both acute COVID-19 patients and Parkinson’s patients, which may imply that high levels of these markers (as seen in the COVID-19 cytokine storm) are associated with a higher clinical severity risk of Parkinsonian symptoms in acute COVID-19 patients (Qin et al., 2016; Qiu et al., 2019; Gialluisi et al., 2020; de Erausquin et al., 2021).